Answers are grounded in this paper and cite their sources.
Analysis shows ribociclib is highly cost-effective compared to palbociclib in postmenopausal women with HR+ advanced breast cancer, highlighting treatment benefits.
Ribociclib improved health outcomes with a minimal relative cost increase and is therefore a highly cost-effective 1 L treatment option vs. palbociclib in patients with HR+/HER2- aBC from the Medicare perspective.
No takes yet. Share an insight, caveat, or question.
Sammons et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: